Literature DB >> 20559404

[Correlation of angiotensin-converting enzyme 2 gene polymorphism with antihypertensive effects of benazepril].

Qing Chen1, Xun Tang, Can-qing Yu, Da-fang Chen, Jun Tian, Yang Cao, Wen-yi Fan, Wei-hua Cao, Si-yan Zhan, Jun Lv, Xiao-xia Guo, Li-ming Li, Yong-hua Hu.   

Abstract

OBJECTIVE: To explore the correlation of rs2106809 from angiotensin-converting enzyme 2 gene with antihypertensive effects of benazepril, as well as its interactions with polymorphisms of angiotensinogen(AGT) and angiotensin II type 1 receptor(AGTR1) gene.
METHODS: Correlation between rs2106809 and blood pressure reduction was estimated based on a field trail with 1 831 hypertensive patients using benazepril for 2 weeks. Generalized multifactor dimensionality reduction (GMDR) was used to explore the interactions of rs2106809 and 8 single nucleotide polymorphisms (SNPs) of AGTR1 gene and 3 SNPs of AGT gene.
RESULTS: rs2106809 was found to be associated with reduction in systolic blood pressure and pulse pressure in women, as well as pulse pressure reduction in men. T allele carriers presented more blood pressure reduction (1.4, 1.3 and 0.9 mmHg/T allele respectively). Gene-gene interactions involving rs2106809 were found in systolic blood pressure reduction of men, and the response to benazepril of non-sensitive genotypes carriers was 8.2 (95% confidence interval: 6.6-9.7) mmHg, lower than that of sensitive genotypes carriers.
CONCLUSION: rs2106809 might act as an independent influencing factor or component of gene-gene interaction in blood pressure reducing effects of benazepril.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20559404

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  4 in total

1.  ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.

Authors:  Gomaa Mostafa-Hedeab
Journal:  Rep Biochem Mol Biol       Date:  2020-04

2.  Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.

Authors:  Ikram Omar Osman; Cléa Melenotte; Philippe Brouqui; Matthieu Million; Jean-Christophe Lagier; Philippe Parola; Andréas Stein; Bernard La Scola; Line Meddeb; Jean-Louis Mege; Didier Raoult; Christian A Devaux
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

3.  ACE polymorphism and COVID-19 outcome.

Authors:  Joris R Delanghe; Marijn M Speeckaert; Marc L De Buyzere
Journal:  Endocrine       Date:  2020-08-07       Impact factor: 3.633

Review 4.  ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.

Authors:  HariOm Singh; Ranjana Choudhari; Vijay Nema; Abdul Arif Khan
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.